Mueller, Sabine;
Fangusaro, Jason;
Thomas, Arzu Onar;
Jacques, Thomas S;
Bandopadhayay, Pratiti;
de Blank, Peter;
Packer, Roger J;
... Witt, Olaf; + view all
(2024)
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group (Dec, 10.1093/neuonc/noad227, 2023).
[Corrigendum].
Neuro-Oncology
, 26
(5)
p. 984.
10.1093/neuonc/noae030.
Preview |
Text
Corrigendum to Consensus framework for conducting phase III clinical trials for children, adolescents, and young adults with.pdf - Accepted Version Download (30kB) | Preview |
Abstract
Sabine Mueller, Jason Fangusaro, Arzu Onar Thomas, Thomas S Jacques, Pratiti Bandopadhayay, Peter de Blank, Roger J Packer, Maryam Fouladi, Antoinette Schouten van Meeteren, David Jones, Arie Perry, Yoshiko Nakano, Darren Hargrave, David Riedl, Nathan J Robinson, Marita Partanen, Michael J Fisher, Olaf Witt, Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group, Neuro-Oncology, 2023;, noad227, https://doi.org/10.1093/neuonc/noad227 In the originally published version of this manuscript, “Tovorafenib” is misspelled as “tovarafenib” in 2 places on page 3 and Reference 65 should be: Kilburn, L.B., Khuong-Quang, DA., Hansford, J.R. et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med (2023). https://doi.org/10.1038/s41591-023-02668-y This error has been corrected.
| Type: | Article |
|---|---|
| Title: | Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group (Dec, 10.1093/neuonc/noad227, 2023) |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1093/neuonc/noae030 |
| Publisher version: | https://doi.org/10.1093/neuonc/noae030 |
| Language: | English |
| Additional information: | © The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Developmental Biology and Cancer Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10214528 |
Archive Staff Only
 |
View Item |
